Clinical Trials on Left-sided Pancreatic Cancer in Chile

Total 11 results

Pontificia Universidad Catolica de Chile

Completed

Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients

Cancer | Breast Cancer | Esophageal Cancer | Lung Cancer | Cardiotoxicity | Radiotherapy; Complications

Chile
Sanofi

Completed

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen (PAPRIKA)

Pancreatic Neoplasms

United States, Brazil, Poland, Russian Federation, Germany, Turkey, India, Belgium, Czech Republic, Mexico, Chile, Finland, Hungary, Italy, Norway, Canada, Colombia, Peru, Slovakia, Spain, United Kingdom
Andes Biotechnologies

Completed

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Cervical Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gall Bladder Cancer | Tumor, Solid

Chile
Hospital San Juan de Dios, Santiago

Completed

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Cisplatin Adverse Reaction | Hearing Loss Ototoxic

Chile
Sanofi
Regeneron Pharmaceuticals

Terminated

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer (VANILLA)

Pancreatic Neoplasm

United States, France, Canada, Poland, Romania, Russian Federation, Germany, Italy, Spain, Switzerland, Bulgaria, India, Belgium, Czech Republic, Mexico, Argentina, Hungary, Colombia, Slovakia, Chile, Austria, Greece, Puerto Rico, Cyprus
Sanofi

Active, not recruiting

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Breast Cancer Metastatic | Pancreatic Carcinoma Metastatic

Spain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
SciClone Pharmaceuticals

Terminated

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

Pancreatic Cancer

United States, Chile, Spain, Brazil, Argentina, France, Germany, Hungary, Netherlands, Peru, Poland, Romania, United Kingdom
Incyte Corporation

Terminated

A Study of Ruxolitinib in Pancreatic Cancer Patients

Pancreatic Cancer

United States, France, Colombia, Israel, Portugal, Netherlands, Chile, Puerto Rico, Sweden, Austria, Denmark, Mexico, Ireland, Switzerland
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Pancreatic Cancer

United States, Canada, Australia, Israel, Singapore, United Kingdom, Germany, Belgium, Romania, Poland, Argentina, Brazil, Chile, Greece, Italy, Mexico, New Zealand
NCIC Clinical Trials Group

Completed

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

United States, Canada, Australia, Singapore, Belgium, United Kingdom, Israel, New Zealand, China, Germany, Brazil, Poland, Italy, Argentina, Romania, Greece, Chile, Hong Kong, Mexico
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom

Clinical Trials on Left-sided Pancreatic Cancer in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations